Form 4: Neuronetics EVP Granted 164,361 Restricted Stock Units

Neuronetics, Inc.'s EVP, General Counsel, Chief Compliance Officer, and Corporate Secretary, William Andrew Macan, was granted 164,361 restricted stock units.

Summary

• William Andrew Macan, Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary of Neuronetics, Inc. (STIM), acquired 164,361 shares of common stock.
• This acquisition, dated December 30, 2025, represents a Restricted Stock Unit (RSU) award with a transaction price of $0 per share.
• The RSUs are scheduled to vest on the earlier of June 30, 2027, or the termination of Mr. Macan's employment from Neuronetics without cause.
• Following this transaction, Mr. Macan directly beneficially owns a total of 691,166 shares.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The RSU grant is a standard compensation practice, indicating executive retention and alignment with shareholder interests, but does not provide new operational or financial performance information that would significantly alter the company's outlook.

Positives

• The grant of Restricted Stock Units (RSUs) aligns the executive's long-term interests with those of shareholders.
• This equity award serves as a retention incentive for a key executive, William Andrew Macan, who holds multiple critical roles within the company.
• The vesting schedule provides a clear commitment timeline for the executive's continued service to the company.

Negatives

• Potential for minor share dilution for existing shareholders upon the vesting and conversion of the RSUs into common stock, although this is a standard aspect of equity compensation.

Future Outlook

NA

Industry Context

This RSU grant is a standard executive compensation practice within the medical device and healthcare technology sectors. Equity awards are commonly used to attract, retain, and incentivize key management personnel by aligning their financial interests with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a prevalent practice across various industries, including medical technology, aligning with global benchmarks for long-term incentive plans.
• The specified vesting schedule, contingent on continued employment and a future date, is typical for such awards, designed to foster executive retention and commitment.
• The transaction being executed under a Rule 10b5-1(c) plan is standard for insiders, providing an affirmative defense against claims of trading on material non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon RSU vesting, but also benefits from enhanced executive alignment with long-term company performance and retention of key management.
• Employees: Standard executive compensation practices can contribute to a positive perception of company stability and a well-structured compensation framework.

Next Steps

• The granted Restricted Stock Units will vest on the earlier of June 30, 2027, or the termination of Mr. Macan's employment without cause.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not contain new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily indicates executive retention and alignment of interests, which are generally positive but not catalysts for a significant re-evaluation of the stock.

Keywords

Neuronetics, STIM, Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, William Andrew Macan, Equity Grant, Corporate Governance